Elliot H. Akama-Garren

TL;DR: In this paper, the authors investigated Treg cell function in a genetically engineered mouse model of lung adenocarcinoma and found that Treg cells suppressed anti-tumor responses in tumor-associated tertiary lymphoid structures (TA-TLSs).

TL;DR: A rapid and sensitive genotyping assay to detect somatic single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1) promoter can establish the diagnosis of low-cellularity tumors like glioma and could be adapted to the point-of-care diagnosis of other lesions similarly defined by highly recurrent somatic mutations.

TL;DR: Fluorescent reporters are developed to rapidly quantify CRISPR/Cas9-mediated deletions and inversions and find that inversion depends on the non-homologous end-joining enzyme LIG4.

TL;DR: The data demonstrate the applicability of GMAP toward the validation of synthetic promoters, identification of potent RNAi constructs, establishment of inducible lentiviral systems, tumor initiation in genetically engineered mouse models, and gene-targeting for the generation of knock-in mice.

TL;DR: The feasibility of using the CRISPR-Cas9 system to model loss of candidate tumor suppressor genes in SCLC is demonstrated, and it is anticipated that this approach will facilitate efforts to investigate mechanisms driving tumor progression in this deadly disease.